Expertise in
2
conditions

Dr. Eunpi Cho

Hematology
Palo Alto Medical Foundation
301 Old San Francisco Rd, 
Sunnyvale, CA 
Expertise in
2
conditions
Palo Alto Medical Foundation
301 Old San Francisco Rd, 
Sunnyvale, CA 

Overview

Eunpi Cho is a Hematologist practicing medicine in Sunnyvale, California.

Dr. Cho is highly rated in 2 conditions, according to our data. Her clinical expertise encompasses Anemia, Myelodysplastic Syndrome (MDS), Non-Hodgkin Lymphoma, and Relapsed Refractory Multiple Myeloma (RRMM).

She is actively involved in clinical research, co-authoring 17 peer reviewed articles and participating in 6 clinical trials.

Specialties

Hematology

Licenses

Internal Medicine in WA

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Palo Alto Medical Foundation
301 Old San Francisco Rd, Sunnyvale, CA 94086

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women With Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer
A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women With Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Drug
Study Drugs: Endoxifen Hydrochloride, Tamoxifen Citrate
Study Phase: Phase 2
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2026
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
Randomized Double-Blind Placebo Controlled Study of Testosterone in the Adjuvant Treatment of Postmenopausal Women With Aromatase Inhibitor Induced Arthralgias
Randomized Double-Blind Placebo Controlled Study of Testosterone in the Adjuvant Treatment of Postmenopausal Women With Aromatase Inhibitor Induced Arthralgias
Enrollment Status: Completed
Publish Date: January 28, 2025
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) VS. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) VS. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Enrollment Status: Terminated
Publish Date: August 23, 2022
Intervention Type: Drug
Study Drugs: Pazopanib, Pazopanib Hydrochloride, Sapanisertib
Study Phase: Phase 1/Phase 2
View 5 Less Clinical Trials

17 Total Publications

The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results.
The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results.
Journal: Nature communications
Published: December 03, 2022
Similar Doctors
Expertise in
42
conditions
Expertise in
42
conditions
Referral may be required

Stanford University

875 Blake Wilbur Dr, 
Palo Alto, CA 
 (9.3 miles away)
650-498-6000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jason Gotlib is a Hematologist practicing medicine in Palo Alto, California. Dr. Gotlib is highly rated in 42 conditions, according to our data. His clinical expertise encompasses Systemic Mastocytosis, Mast Cell Activation Syndrome (MCAS), Myelofibrosis, Bone Marrow Aspiration, and Tissue Biopsy. Dr. Gotlib is currently accepting new patients.

Expertise in
36
conditions
Expertise in
36
conditions
Referral may be required

Stanford Hospital And Clinics

300 Pasteur Dr, 
Stanford, CA 
 (9.2 miles away)
650-723-0822
Languages Spoken:
English
See accepted insurances
Offers Telehealth

David Miklos is a Hematologist practicing medicine in Stanford, California. Dr. Miklos is highly rated in 36 conditions, according to our data. His clinical expertise encompasses Chronic Graft Versus Host Disease (cGvHD), B-Cell Lymphoma, Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
23
conditions
Expertise in
23
conditions
Referral may be required

Stanford Hospital And Clinics

965 High St, 
Palo Alto, CA 
 (8.6 miles away)
650-723-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Michaela Liedtke is a Hematologist practicing medicine in Palo Alto, California. Dr. Liedtke is highly rated in 23 conditions, according to our data. Her clinical expertise encompasses Primary Amyloidosis, Acute Lymphoblastic Leukemia (ALL), Multiple Myeloma, Bone Marrow Aspiration, and Bone Marrow Transplant.

Frequently Asked Questions about Dr. Eunpi Cho

How do I make an appointment with Dr. Eunpi Cho?

You can book an appointment with Dr. Eunpi Cho by calling their office at 408-739-6000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Eunpi Cho a top-rated expert for Anemia?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Eunpi Cho is classified as an Advanced expert for Anemia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Eunpi Cho specialize in?

While Dr. Eunpi Cho is a Hematology, they have specific expertise in Anemia, Myelodysplastic Syndrome (MDS), and Non-Hodgkin Lymphoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Eunpi Cho participate in research or clinical trials?

Yes. Dr. Eunpi Cho has published 17 articles and abstracts on conditions like Anemia. You can view a list of Dr. Eunpi Cho's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Cho's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile